Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with Multikine

Archives of Otolaryngology - Head and Neck Surgery

Volumn 129, Issue 8, 2003, Pages 874-881

  Feinmesser, Raphael ^a,b   Hardy, Britta ^a,b   Sadov, Rima ^a,b   Shwartz, Ariel ^a,b   Chretien, Paul ^b,c   Feinmesser, Meora ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Cel Sci Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOMETACIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MULTIKINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC SULFATE;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTER; FOLLOW UP; HEAD AND NECK CANCER; HEADACHE; HEART PALPITATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; MACROPHAGE; MALE; NATURAL KILLER CELL; SEPSIS; SQUAMOUS CELL CARCINOMA; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; INDOMETHACIN; INJECTIONS, INTRALESIONAL; INTERLEUKINS; MALE; MIDDLE AGED; TREATMENT OUTCOME; ZINC SULFATE;

EID: 0042591473     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.129.8.874     Document Type: Article

References (30)

1. Lapointe H, Lampe H, Banerjee D. Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses, Otolaryngol Head Neck Surg. 1992;106:149-158.
2. Katz AE. Update on immunology of head and neck cancer. Med Clin North Am. 1993;77:625-631.
3. Hadden JW, Endicott J, Baekey P, Skipper P, Hadden EM. Interleukins and countersuppression induce immune regression of head and neck cancer. Arch Otolaryngol Head Neck Surg. 1994;120:395-403.
4. Clark DR. Immunology aspects of head and neck cancer. Hematol Oncol Clin North Am. 1991;5:797-802.
5. Hadden JW. Immunology of head and neck cancer: prospects for immunotherapy. Clin Immunother. 1995;3:362-383.
6. Hadden JW. The treatment of zinc deficiency in an immunotherapy. Int J Immunopharmacol. 1995;17:697-701.
7. Pulley MS, Nagendran V, Edwards JW, Dumonde DC. Intravenous intralesional and endolymphatic administration of lymphokines in human cancer. Lymphokine Res. 1986;5:157-163.
8. Clayman GL, Taylor DL, Liu FJ, Lavedam P, Savage HE, Schantz SP. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells. Laryngoscope. 1993;103:299-307.
9. Alexander JP, Kudoh S, Melsop KA, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993;53:1380-1387.
10. Richtsmeier WJ. Immunology of head and neck cancer. Bull Am Coll Surg. 1997;82:32-53.
11. Young MRI, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer. 1996;67:333-338.
12. Rosenberg SA, Lotzi MT, Muul LM, et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676-1680.
13. Pulley MS, Nagedran V, Edwards JM, Dumonde DC. Intravenous intralesional and endolymphatic administration of lymphokines in human cancer. Lymphokine Res. 1986;5:157-163.
14. Papermaster BW, Holterman OA, Klein E, et al. Preliminary observations on tumor regression induced by local administration of lymphoid cell culture supernatant fraction in patients with cutaneous metastatic lesions. Clin Immunol Immunopathol. 1976;5:31-47.
15. Vlock DR, Synderman CH, Johnson JT, et al. Phase 1 b trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother Emphasis Tumor Immunol. 1994;15:134-139.
16. Verma S, Hiby SE, Loke Y, King A. Human decidual natural killer cells express the receptor for and respond to the cytokine interleukin 15. Biol Reprod. 2000;62:959-968.
17. Delfino DV, DiMarco B, Marchetti C, et al. Effect of interleukin-2 on generation of natural killer cells: role of major histocompatibility complex class I in B6 and TAP-1-/- mice. J Chemother. 2000;12:160-166.
18. Wang K, Frank D, Ritz J. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 2000;95:3183-3190.
19. Kottgen E, Fabricius HA, Stahn R, Gerok W. T-lymphocyte activation: studies on the function of mediator proteins [in German]. Klin Wochenschr. 1981;59:669-674.
20. Musiani P, De Campora E, Valitutti S, et al. Effect of low doses of interleukin-2 injected perilymphatically and peritumorally in patients with advanced primary head and neck squamous cell carcinoma. J Biol Response Mod. 1989;8:571-578.
21. Cortesina G, De Stefani A, Giovarelli M, et al. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer. 1988;62:2482-2485.
22. Saito T, Kakiuti H, Kuki K, et al. Clinical evaluation of local administration of RIL-2 in head and neck cancer. Nippon Jibiinkoka Gakkai Kaiho. 1989;92:1265-1270.
23. Cortesina G, De Stefani A, Galeazzi E, et al. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin-2 injected perilymphatically. Br J Cancer. 1994;69:572-576.
24. Wolf GT, Lovett E, Peterson KA, Baker SR. Lymphokine productions and lymphocyte subpopulations in patients with head and neck squamous cell carcinoma. Arch Otolaryngol. 1984;110:731-739.
25. Maisel RH, Ogura JH. Dinitrochlorobenzene skin sensitization and peripheral lymphocyte count predictors of survival in head and neck cancer. Ann Otol Rhinol Laryngol. 1976;85(pt 1):517-522.
26. Jenkins VR, Griffiths CM, Ray P, Perry RR, Chion MA. Radiotherapy in head and neck cancer: role of lymphocyte response and clinical stage. Arch Otolaryngol. 1980;106:414-416.
27. Stefano S, Kermian R, Abbate J. Serial studies of immunocompetence in head and neck cancer patients undergoing radiation therapy. AJR Am J Roentgenol. 1976;126:880-886.
28. Estnazi DP, Parsa JJ, Ershon EG. Depressed PMNC blastogenic response in patients with cancer of the head and neck, a study of IL-2 products, IL-2 consumption and IL-2 receptor expression. Laryngoscope. 1989;89:151-157.
29. Paul WE. Pleiotropy and redundancy: T-cell derived lymphokines in the immune response. Cell. 1989;57:521-524.
30. Grimm EA, Minzunder A, Zhang AL. Lymphokine-activated killer cell phenomenon: lysis of natural killer resistant fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823-1841.